Naveen Pemmaraju/mdanderson.org
Jun 10, 2025, 04:55
Naveen Pemmaraju: Proud to be one of the featured lead authors for one of the five selected abstracts for the Plenary Session at ASCO
Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a post on LinkedIn:
“Proud to be one of the featured lead authors for one of the five selected abstracts for the Plenary Session at American Society of Clinical Oncology (ASCO) | Dr Andrew Kuykendall presented on behalf of our group , the VERIFY program, a positive randomized Ph3 study of Rusfertide, first-in-class hepcidin mimetic for patients with phlebotomy-dependent Polycythemia Vera (PV).”
More posts featuring Naveen Pemmaraju.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 10, 2025, 22:13
Aug 10, 2025, 21:48
Aug 10, 2025, 21:21
Aug 10, 2025, 19:51
Aug 10, 2025, 18:01
Aug 10, 2025, 15:36
Aug 10, 2025, 14:54